• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for TYMLOS issued to RADIUS HEALTH INC

    9/21/21 5:24:53 AM ET
    $RDUS
    Industrial Specialties
    Consumer Discretionary
    Get the next $RDUS alert in real time by email
    New Drug Application (NDA): 208743
    Company: RADIUS HEALTH INC
    • Email
    • Medication Guide
    • Summary Review

    Products on NDA 208743

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    TYMLOS ABALOPARATIDE 3.12MG/1.56ML (2MG/ML) SOLUTION;SUBCUTANEOUS Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 208743

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    04/28/2017 ORIG-1 Approval Type 1 - New Molecular Entity and Type 4 - New Combination STANDARD Label (PDF)
    Letter (PDF)
    Review
    Summary Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208743Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000SumR.pdf
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    09/20/2021 SUPPL-9 Efficacy-Labeling Change With Clinical Data

    Label is not available on this site.

    10/23/2020 SUPPL-7 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208743s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/208743Orig1s007ltr.pdf
    06/20/2018 SUPPL-4 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s004ltr.pdf
    10/17/2018 SUPPL-3 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s003ltr.pdf
    02/05/2018 SUPPL-1 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208743Orig1s001ltr.pdf

    Labels for NDA 208743

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    10/23/2020 SUPPL-7 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208743s007lbl.pdf
    10/17/2018 SUPPL-3 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s003lbl.pdf
    06/20/2018 SUPPL-4 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s004lbl.pdf
    02/05/2018 SUPPL-1 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208743s001lbl.pdf
    04/28/2017 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf
    Get the next $RDUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RDUS

    DatePrice TargetRatingAnalyst
    12/2/2024$22.00Neutral
    Goldman
    5/30/2024Sell → Neutral
    Seaport Research Partners
    2/28/2024$17.50Neutral → Sell
    Seaport Research Partners
    12/14/2023Neutral
    Seaport Research Partners
    6/8/2022$8.00Underperform → Neutral
    BofA Securities
    5/23/2022$7.00Mkt Perform
    SVB Leerink
    12/10/2021$18.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    12/10/2021$33.00 → $12.00Buy → Neutral
    Goldman Sachs
    More analyst ratings